Article Text

Download PDFPDF
Use and monitoring of low dose rituximab in myasthenia gravis
  1. Stefan Blum1,
  2. David Gillis2,3,
  3. Helen Brown3,
  4. Richard Boyle3,
  5. Robert Henderson1,
  6. David Heyworth-Smith3,
  7. Patrick Hogan2,3,
  8. Paul Kubler1,
  9. Cecilie Lander1,
  10. Nicole Limberg4,
  11. Peter Pillans3,
  12. Kerri Prain2,
  13. Christopher Staples5,
  14. Michael Walsh3,
  15. Pamela McCombe1,
  16. Richard Wong2,3
  1. 1Royal Brisbane Hospital, Brisbane, Australia
  2. 2Pathology Queensland, Brisbane, Australia
  3. 3Princess Alexandra Hospital, Brisbane, Australia
  4. 4St Andrews Hospital, Brisbane, Australia
  5. 5Mater Hospital, Brisbane, Australia
  1. Correspondence to Dr S Blum, Department of Neurology, Royal Brisbane Hospital, Butterfield Street, Herston QLD 4029, Australia; stefan_blum{at}


Background Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. Rituximab (RTX), a monoclonal antibody to CD20, leads to B lymphocyte depletion and has been used in some autoimmune disorders, including small case series of myasthenia gravis patients.

Methods A retrospective analysis was performed of all patients with acetylcholine receptor (AChR) (11 subjects) or muscle specific kinase antibody (MuSK) positive myasthenia gravis (three subjects), who had been treated with RTX in Brisbane, Australia. In most patients 1 g of RTX, in two divided doses, was given. Patients were monitored by serial clinical assessments, flow cytometry of peripheral blood B lymphocytes and antibody testing.

Results RTX led to a significant improvement in symptoms in 11 of 14 patients. Doses of immunosuppressive medications were able to be reduced in 12 of 14 patients but medications could be completely ceased in only one patient. A demonstrable reduction of autoantibody levels was found in only three AChR positive patients and one MuSK positive patient, independent of clinical improvement. Peripheral blood B lymphocyte depletion was achieved in 13 out of 14 patients. B lymphocyte recovery occurred between 9 and 30 months post RTX (median 12.3 months) and was consistently associated with worsening of clinical symptoms.

Conclusion Rituximab at a dose of 1 g appears to be beneficial in the treatment of patients with severe myasthenia gravis. Serial monitoring of peripheral blood B lymphocytes appears to be useful in guiding the need for further RTX therapy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding SB was funded by the Royal Brisbane and Women's Hospital Research Scholarship.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Royal Brisbane and Women's Hospital Research Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.